Link to Full Article Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™ LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-05-22 02:08:542020-05-29 02:14:28CALCIMEDICA RAISES $15 MILLION IN SERIES C FINANCING ROUND LED BY VALENCE LIFE SCIENCES
LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-05-21 02:54:512020-05-22 02:55:47CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
Link to Full Article MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the first quarter of 2020 and provided a corporate and clinical update. Key First Quarter 2020 and Subsequent […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-05-14 04:00:452020-05-15 04:01:59Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-05-12 04:05:032020-05-15 04:06:1512 May 2020 – Posting of Annual Report and Notice of AGM
Link to Full Article Company funded through to Q4 2021 Patient recruitment for XF-73 Phase 2b trial temporarily paused due to COVID-19 pandemic Brighton, United Kingdom – 29 April 2020 – Destiny Pharma (“the Company”; AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-04-29 05:16:472020-04-30 05:18:48Audited results for the year ended 31 December 2019 and clinical development update
Link to Full Article Melbourne, Australia – 29 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has signed a heads of terms sales agreement with Monaghan Medical Corporation, a US subsidiary of Trudell Medical Limited, the parent company of a multinational group of leading companies […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-04-29 04:56:142020-04-30 05:12:44Adherium progresses U.S. sales agreement with respiratory device U.S. market leader Monaghan Medical Corporation, a member of the Trudell Medical Group of Companies
Link to Full Article Melbourne, Australia – 24 April 2020: Adherium (ASX:ADR) today announced the promotion of Mr Mike Motion from Chief Operating Officer to the role of Chief Executive Officer, replacing Mr Jeremy Curnock Cook who has held the position on an interim basis. Mike will also join the Board as an Executive Director, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-04-24 04:48:532020-04-30 04:55:46Adherium announces appointment of Mr. Mike Motion as Chief Executive Officer and Ms. Anne Bell as Chief Financial Officer
Link to Full Article Melbourne, Australia – 21 April 2020: Adherium (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, today announced a strategic device hardware and software development partnership with Planet Innovation (PI). This development will enhance Adherium’s leading device coverage position in both asthma and COPD with sensors […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-04-21 04:44:072020-04-30 04:48:25Adherium and Planet Innovation partner to develop inhaled medication adherence devices and enhanced digital software platform
Link to Full Article Melbourne, Australia – 16 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has agreed a US disease management collaboration with Pennsylvania-based HGE Health. Both parties will rapidly evaluate and integrate Adherium’s sensor and software technology into HGE Health’s established telemedicine platform […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-04-16 04:58:322020-04-17 05:09:53Adherium announces first US disease management collaboration in COPD with HGE Health
Link to Full Article 14 April 2020 – Adherium (ASX:ADR) announces that James Ward-Lilley who has been consulting to Adherium over recent months has joined the Adherium Board of Directors, and following the untimely death of Thomas Lynch, James has also been appointed Chairman of the Board. Mr. Ward-Lilley commented “I am pleased to be […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-04-14 05:10:512020-04-17 05:17:36Appointment of Mr. James Ward-Lilley as a Director and Chairman
CALCIMEDICA RAISES $15 MILLION IN SERIES C FINANCING ROUND LED BY VALENCE LIFE SCIENCES
/in CalcimedicaLink to Full Article Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™ LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has […]
CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
/in CalcimedicaLA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called […]
Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the first quarter of 2020 and provided a corporate and clinical update. Key First Quarter 2020 and Subsequent […]
12 May 2020 – Posting of Annual Report and Notice of AGM
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that […]
Audited results for the year ended 31 December 2019 and clinical development update
/in Destiny PharmaLink to Full Article Company funded through to Q4 2021 Patient recruitment for XF-73 Phase 2b trial temporarily paused due to COVID-19 pandemic Brighton, United Kingdom – 29 April 2020 – Destiny Pharma (“the Company”; AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global […]
Adherium progresses U.S. sales agreement with respiratory device U.S. market leader Monaghan Medical Corporation, a member of the Trudell Medical Group of Companies
/in AdheriumLink to Full Article Melbourne, Australia – 29 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has signed a heads of terms sales agreement with Monaghan Medical Corporation, a US subsidiary of Trudell Medical Limited, the parent company of a multinational group of leading companies […]
Adherium announces appointment of Mr. Mike Motion as Chief Executive Officer and Ms. Anne Bell as Chief Financial Officer
/in AdheriumLink to Full Article Melbourne, Australia – 24 April 2020: Adherium (ASX:ADR) today announced the promotion of Mr Mike Motion from Chief Operating Officer to the role of Chief Executive Officer, replacing Mr Jeremy Curnock Cook who has held the position on an interim basis. Mike will also join the Board as an Executive Director, […]
Adherium and Planet Innovation partner to develop inhaled medication adherence devices and enhanced digital software platform
/in AdheriumLink to Full Article Melbourne, Australia – 21 April 2020: Adherium (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, today announced a strategic device hardware and software development partnership with Planet Innovation (PI). This development will enhance Adherium’s leading device coverage position in both asthma and COPD with sensors […]
Adherium announces first US disease management collaboration in COPD with HGE Health
/in AdheriumLink to Full Article Melbourne, Australia – 16 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has agreed a US disease management collaboration with Pennsylvania-based HGE Health. Both parties will rapidly evaluate and integrate Adherium’s sensor and software technology into HGE Health’s established telemedicine platform […]
Appointment of Mr. James Ward-Lilley as a Director and Chairman
/in AdheriumLink to Full Article 14 April 2020 – Adherium (ASX:ADR) announces that James Ward-Lilley who has been consulting to Adherium over recent months has joined the Adherium Board of Directors, and following the untimely death of Thomas Lynch, James has also been appointed Chairman of the Board. Mr. Ward-Lilley commented “I am pleased to be […]